Cevipabulin is primarily investigated for its potential in cancer treatment. It functions as a microtubule destabilizing agent, which disrupts the normal function of microtubules in cells. This disruption is particularly effective in inhibiting the growth of cancer cells, as it prevents them from dividing and proliferating. Research has shown its efficacy in various preclinical models of cancer, including breast, lung, and prostate cancers. Additionally, Cevipabulin is being explored for its ability to enhance the effects of other chemotherapy agents, potentially improving overall treatment outcomes. Its unique mechanism of action makes it a promising candidate for overcoming drug resistance in certain types of cancer. Ongoing studies aim to further evaluate its safety and effectiveness in clinical settings.